Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/8/2024 | $38.00 → $16.00 | Overweight → Equal-Weight | Stephens | |
| 10/11/2024 | $35.00 | Overweight | KeyBanc Capital Markets | |
| 8/9/2024 | $28.00 → $33.00 | Hold → Buy | Truist | |
| 7/24/2024 | $83.00 → $69.00 | Buy → Hold | Jefferies | |
| 5/30/2024 | $405.00 | Outperform | Robert W. Baird | |
| 5/30/2024 | $83.00 | Neutral | Robert W. Baird | |
| 4/22/2024 | $40.00 | Buy | Citigroup | |
| 3/28/2024 | $439.00 | Neutral → Underperform | BofA Securities |
Stephens downgraded Evolent Health from Overweight to Equal-Weight and set a new price target of $16.00 from $38.00 previously
KeyBanc Capital Markets initiated coverage of Evolent Health with a rating of Overweight and set a new price target of $35.00
Truist upgraded Evolent Health from Hold to Buy and set a new price target of $33.00 from $28.00 previously
Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)%.Adjusted EBITDA of $31.8 million resulting in an Adjusted EBITDA margin of 5.1%.Revises outlook for Adjusted EBITDA for 2024.Reiterates average annual long-term revenue and average Adjusted EBITDA growth rate targets.Announces record six new contract agreements in the quarter.WASHINGTON, Nov. 7, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions th
-- Diluted EPS of $1.36; Adjusted Diluted EPS of $1.62 -- -- Reaffirms 2024 Adjusted Diluted EPS Guidance Floor of Greater Than $6.80 -- Adjusted diluted EPS of $1.62 in the third quarter of 2024.Premium and service revenues of $36.9 billion in the third quarter of 2024.Membership increases of 22% in Marketplace and 49% in Medicare Prescription Drug Plans, compared to the third quarter of 2023.Continued execution on capital deployment with $1.2 billion of share repurchases during the third quarter of 2024 and an additional $380 million in October, bringing full-year repurchases to $2.4 billion through October 2024.ST. LOUIS, Oct. 25, 2024 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the
Reaffirms Full Year 2024 Earnings Guidance Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today reported third quarter 2024 GAAP earnings per diluted share of $5.65 and adjusted earnings per diluted share of $6.01. Financial results are summarized below: Three months ended Nine months ended September 30, September 30, 2024 2023 2024 2023 (In millions, except per-share results) Premium Revenue $ 9,694 $ 8,240 $ 28,644 $ 24,167 Total Revenue $ 10,340 $ 8,548 $ 30,151
Cantor Fitzgerald analyst Sarah James reiterates Molina Healthcare (NYSE:MOH) with a Overweight and maintains $406 price target.
Expands Payer-Agnostic Care Delivery Capabilities Serving Over 129,000 Beneficiaries Across 17 States
8-K - MOLINA HEALTHCARE, INC. (0001179929) (Filer)
8-K - MOLINA HEALTHCARE, INC. (0001179929) (Filer)
8-K - MOLINA HEALTHCARE, INC. (0001179929) (Filer)
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
SC 13G - CENTENE CORP (0001071739) (Subject)
SC 13G/A - MOLINA HEALTHCARE, INC. (0001179929) (Subject)
SC 13G/A - CENTENE CORP (0001071739) (Subject)
PEMBROKE PINES, Fla., Nov. 7, 2024 /PRNewswire/ -- Sunshine Health, Florida's largest managed care organization and a Centene Corporation company (NYSE:CNC), announced today Charlene Zein has been named Plan President and Chief Executive Officer, effective Nov. 3, 2024. Zein has nearly two decades of experience in the healthcare industry, including various leadership roles of increasing scope and responsibility at Sunshine Health since joining in 2019. She most recently served as Sunshine Health Chief Product President, where she had oversight of all of Sunshine Health's Medi
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
ST. LOUIS, Aug. 15, 2024 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the Company") announced today that it has appointed Thomas R. Greco to the Centene Board of Directors, effective Aug. 9, 2024. Mr. Greco's term will run through the Company's 2025 annual meeting of stockholders. The appointment of Mr. Greco expands Centene's Board of Directors to 11 members. Mr. Greco is a seasoned operator and executive who brings more than four decades of public company leadership and expertise to Centene. Over the course of his career, he has implemented growth strategies and fostered
Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today announced the closing of its previously announced offering of $750 million aggregate principal amount of 6.250% senior notes due 2033 (the "Notes") sold in a private offering to individuals reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to certain persons outside the United States in reliance on Regulation S under the Securities Act. The Notes bear interest at a rate of 6.250% per annum. Interest on the Notes is payable semi-annually in arrears on January 15 and July 15 of each year, commencing July 15, 2025, and accrues from N
Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today announced that it priced $750 million aggregate principal amount of its 6.250% senior notes due 2033 (the "Notes") to be sold in a private offering to individuals reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to certain persons outside the United States in reliance on Regulation S under the Securities Act. The offering is expected to close on or about November 18, 2024 (such actual closing date, the "Settlement Date"), subject to the satisfaction of customary closing conditions. The Notes will not be guaranteed by any of the C
Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today announced that it intends to privately offer, subject to market and other conditions, $500 million aggregate principal amount of senior notes due 2033 (the "Notes"). The Company will make the offering pursuant to an exemption under the Securities Act of 1933, as amended (the "Securities Act"). The initial purchasers will sell the Notes only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act and to certain persons outside the United States in reliance on Regulation S under the Securities Act ("Regulation S"). The Notes will not be guaranteed by any of the Company's sub
4 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)
4 - CENTENE CORP (0001071739) (Issuer)